Hanvet Pet Health

Hanvet Pet Health, based in Shanghai, China, is dedicated to manufacturing innovative veterinary pharmaceuticals and health products for pets, focusing on effective treatments for various diseases to enhance animal well-being. Hanvet Biopharmaceutical Technology Co. , Ltd. develops veterinary health solutions, having its headquarters in Shanghai, China.

The company was founded by professionals with industry experience, although specific details about the founder's previous ventures are not publicly available. They do not have known subsidiaries or a parent company, and no significant pivots in business strategy have been reported. Hanvet Biopharmaceutical Technology Co. , Ltd.

specializes in veterinary pharmaceuticals and health products for pets, primarily focusing on effective treatment solutions for various diseases. Their core product offerings include a range of medications such as Cyclosporin Oral Solution, a first-of-its-kind immunosuppressive oral liquid approved for pet use, and Mortect®, which targets both internal and external parasitic infections in dogs and cats. Additionally, they provide dermatological treatments like Comfskin, designed for dermatophytosis caused by specific fungal infections. These products are designed to address specific health issues in pets, thereby enhancing overall animal well-being.

Hanvet primarily serves veterinary practices, pet owners, and distributors within the domestic Chinese market, expanding their reach into select international markets such as Southeast Asia and other regions where veterinary care is developing. Hanvet generates revenue through direct sales of its veterinary health products to veterinary clinics and pet owners, utilizing a B2B and direct-to-consumer model. The company’s flagship products, including the Cyclosporin Oral Solution and Mortect®, are marketed through established partnerships with veterinary hospitals and clinics, facilitating easy access for pet owners seeking effective health solutions for their animals. Transactions typically involve bulk purchases by veterinary clinics and retail partnerships, allowing for competitive pricing and streamlined distribution.

The pricing structure for individual products is designed to reflect the unique formulation and efficacy of their medications, ensuring value for veterinary professionals and pet owners alike. Hanvet’s focus on research and development further supports their revenue model by continuously introducing innovative solutions to meet the evolving needs of pet health care.